Proposed Acquisition of Ellipses Pharma Limited
Wolfram Resources signs non-binding MoU to acquire Ellipses Pharma, an oncology drug development company, targeting completion in early 2027.
Select text to share a quote on X · sign in to keep highlights & notes in your WFR notes
Further to the announcement on 16 November 2026, Wolfram Resources Plc (LSE: WFR), the Main Market listed special purpose acquisition company whose ordinary shares are traded on the Equity Shares (Shell Companies) listing category, is pleased to announce that it has signed a non-binding Memorandum of Understanding ("MoU") with Ellipses Pharma Limited ("Ellipses"), the London-based oncology drug development company, in respect of the proposed acquisition of the entire issued share capital of Ellipses (the "Proposed Acquisition") and the re-listing of the enlarged group on the Main Market in the Equity Shares (Commercial Companies) category (the “Proposed Relisting”).
If completed, the Proposed Acquisition would give the Company and its shareholders exposure to a portfolio of clinical and near-clinical oncology assets with an attractive growth profile, while providing Ellipses with a public markets platform and access to additional capital to support the continued development of its pipeline.
Highlights
The Proposed Acquisition would bring Ellipses' clinical-stage oncology portfolio to the Main Market.
Consideration for the Proposed Acquisition is expected to be satisfied in new Wolfram ordinary shares, with final terms to be agreed following due diligence.
A fundraise is expected to be conducted in conjunction with the Proposed Relisting (the “Proposed Fundraise”).
Detailed technical, financial and legal due diligence begins immediately, with completion of the Proposed Acquisition, Proposed Fundraise and Proposed Relisting (together the “Proposed Transaction”) targeted for early 2027.
About Ellipses Pharma
Ellipses Pharma is a London-headquartered drug development company focused exclusively on cancer. Founded in 2017 by Professor Sir Chris Evans OBE, Ellipses sources candidate assets globally, selects them through independent expert review utilising its global Scientific Advisory Group and advances them through clinical development. The Scientific Advisory Group was established by Ellipses and includes more than 300 leading oncology experts, across multiple tumour types and therapeutic modalities.
Its portfolio spans multiple clinical-stage programmes, with trial sites across the United States, Europe and Asia Pacific. This includes EP0031 (lunbotinib), a next-generation selective RET inhibitor in Phase 2 development for RET-altered non-small cell lung cancer, partnered with Kelun-Biotech, and EP0062 (vosilasarm), an oral selective androgen receptor modulator in Phase 2 development in ER+/HER2- breast cancer. Further information is available at www.ellipses.life.
Professor Sir Chris Evans OBE, Chair and Founder of Ellipses Pharma Limited, said:
"Our company has been focused resolutely on the development of promising drug candidates and the progress made with our pipeline, including encouraging results from our clinical trials for both EP0031 and EP0062, indicates that this is now an optimal time to move towards a public listing. The transaction with Wolfram will accelerate Ellipses’ plan to deliver the next stage of its evolution as a public company. The ability also to raise additional capital from public company investors will drive the continued growth of our portfolio and enable our current shareholders to realise that growth in the longer term. We look forward to working with the Wolfram team to deliver the transaction."
Graeme Muir, Executive Director of Wolfram Resources Plc, said:
"We are excited to be working with such a strong management team that brings with it years of experience and a proven track record. We now move to detailed due diligence, and we believe this transaction can deliver real value for Wolfram shareholders."
Appointment of Sponsor and Financial Adviser
The Company has appointed Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg") as Sponsor and Financial Adviser in respect of the Proposed Transaction.
Conditions
The Proposed Transaction will be conditional on, among other things, satisfactory technical, financial and legal due diligence, agreement of final terms and definitive documentation, the approval by the Financial Conduct Authority (“FCA”) of, and publication by the Company of, a prospectus relating to the enlarged group, shareholder approval, appropriate approval by the Panel on Takeovers and Mergers in relation to a Rule 9 Waiver, and admission of the enlarged issued share capital to the Official List (ESCC category) and to the Main Market.
Cleaned text: letterheads, contacts and legal notices removed. Official copy: FCA National Storage Mechanism ↗ · Company filings. Not investment advice.